Despite tremendous promise as a female-controlled HIV prevention strategy, implementation of preexposure prophylaxis (PrEP) among women has been limited, in part because of disparate efficacy results from randomized trials in this population. This review synthesizes existing evidence regarding PrEP efficacy for preventing HIV infection in women and considerations for delivering PrEP to women.
INTRODUCTION
HIV/AIDS is the leading cause of death among women of reproductive age, and a combination of biological, behavioral, and sociocultural factors result in women bearing a disproportionate burden of the global HIV epidemic [1, 2] . HIV prevention strategies available to women at risk of sexual transmission include abstinence from sexual activity, female and male condoms, and antiretroviral therapy (ART) use or voluntary male medical circumcision by their partners; however, all of these strategies depend on male partner cooperation. Tenofovir disoproxil fumarate/emtricitabine (TDF)-based preexposure prophylaxis (PrEP) is a novel prevention strategy in which HIV uninfected individuals use an oral antiretroviral medication, such as chemoprophylaxis to reduce HIV acquisition [3] . PrEP holds tremendous promise as a female-controlled prevention approach, and international normative bodies recommend PrEP for persons at substantial HIV risk, including women [4 
TEXT OF REVIEW
Randomized clinical trials of preexposure prophylaxis among women Five double-blinded, placebo-controlled randomized clinical trials of daily oral TDF-based PrEP that included heterosexual women were conducted [9,10 && ,11 && ,12-14,15 && ] ( Table 1 ). All trials were carried out in settings with high HIV burden and study subjects received a comprehensive package of HIV prevention services, including frequent HIV testing, risk reduction and adherence counselling, condoms, and treatment for sexually transmitted infections (STI). Participants received intensive adherence counseling to take study drug once per day, and multiple methods were used to measure adherence, including self-report, daily diaries, clinic-based counts of returned pills and bottles, and testing archived blood samples for tenofovir. Despite similarities in study design and analytic approach, the primary intent-to-treat efficacy results varied substantially across trial populations.
Three of the five studies found that daily oral PrEP reduced the risk of HIV acquisition overall and in subgroup analyses of women. In the Partners PrEP Study, which included 1785 Kenyan and Ugandan women with a mutually disclosed HIV-infected partner, PrEP efficacy among women was 66 and 71% for the two PrEP medications tested, and PrEP efficacy did not differ substantially between men and women [9] . In further analyses, the protective effect of PrEP was consistent in subgroups of women at high risk for HIV acquisition [10 && ]. PrEP efficacy among women in the TDF2 (Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually-Active Young Adults in Botswana) study was 49%, although the small sample size limited statistical precision [12] . Although women comprised only 20% of participants in the Bangkok Tenofovir Study (BTS), PrEP efficacy among this subgroup was 79% [13] . In contrast, two trials among African women, ( 
KEY POINTS
Clinical trial data demonstrate that daily tenofovirbased oral PrEP prevents HIV acquisition among women, when taken with sufficient adherence.
Pharmacokinetic studies provide evidence that daily dosing of tenofovir-based oral PrEP reaches concentrations in vaginal tissues that are consistent with levels needed for HIV prevention.
Evidence from clinical trials and emerging data from open-label studies demonstrate that women who are at risk of HIV and motivated to use PrEP can adhere sufficiently to the daily regimen and be protected against HIV.
Innovative strategies to motivate women at risk to use daily PrEP and scalable adherence support strategies need to be identified and integrated into delivery models. && ]. One proposed explanation for this difference is that women in the Partners PrEP Study were primarily exposed to HIV by chronically infected men, who were potentially less infectious than acutely infected men [27] . Although infectivity is a strong predictor of HIV transmission, most infections in generalized HIV epidemics are transmitted from persons with chronic HIV [28, 29] ; and thus it is likely that most transmissions in FEM-PrEP and VOICE were as well. The overall protective effect of PrEP was 76-78%, among all HIV uninfected participants and 72-84%, among women whose partner had a viral load !50 000 copies/ml in the Partners PrEP Study, providing evidence that the prevention benefit of PrEP was not attenuated with exposure to high HIV viral load [10 && ]. Animal models have demonstrated that the protective effect of TDF-based PrEP does not diminish over time, regardless of the number of challenges, suggesting that there may not be a threshold effect of PrEP when taken with sufficient adherence [30 & ,31]. The high pregnancy incidence rate among women initiating oral contraceptives during FEM-PrEP initially suggested a potential interaction between oral contraceptives and PrEP [32,33 & ]. However, low adherence to oral contraceptives, especially among new users, is thought to be the driving factor behind this pregnancy incidence and women who adopted oral contraceptives at study enrollment were also less likely to adhere to study drug [16
TDF-based PrEP does not interact with oral, injectable or implantable contraception to reduce either the effectiveness of contraceptives to prevent unintended pregnancy nor the HIV prevention benefit of PrEP [33
Indeed, PrEP is one strategy that could mitigate concern regarding the potential increased risk for HIV acquisition among women using progestin-based injectable contraception [36].
Behavioral factors influencing preexposure prophylaxis effectiveness among women
Although challenging to accurately measure, motivation to prevent HIV acquisition is likely tied to selfperceived risk, which in turn influences adherence to HIV prevention strategies [37 ]. In qualitative interviews, VOICE participants acknowledged that their trial participation was motivated by increased HIV risk from male partners with additional sexual partners, however women often had to compromise study drug adherence and keep their trial participation covert to maintain these relationships [42 && ]. Across trials, personal assessment of high HIV risk, coupled with social and clinic-based support, facilitated greater self-efficacy to adhere to daily oral PrEP. HIV-uninfected participants in the Partners PrEP Study had known exposure to HIV from their mutually disclosed HIV infected study partner and both partners received adherence counselling during the trial [39 && ]. PrEP provided a solution to the 'discordance dilemma' by simultaneously preventing HIV acquisition and maintaining the partnership, especially prior to ART initiation by the HIV infected partner [43] . Low or no adherence to PrEP in the Partners PrEP Study was associated with no or infrequent sex with a study partner, suggesting that participants modified their PrEP use based on fluctuations in their sexual activity and perceived HIV risk [11 && ,41]. Participants in the BTS were self-identified injection drug users attending drug treatment centers who had potential for parenteral and sexual exposure, and 93% of participants elected to attend daily study visits [40 & ]. Although participants did receive compensation for each study visit, these characteristics also suggest a high motivation for risk reduction.
Despite The HIV prevention benefit of preexposure prophylaxis requires adherence
The conflicting results across trials regarding the benefit of PrEP for women have challenged the HIV prevention community. However, when analyzed collectively, there is a clear conclusion that daily oral TDF-based PrEP is protective for women, established through subgroup analyses, consistency across studies when adherence is evaluated, and bolstered by analogous data from men. Like any medication, adherence is required for PrEP to be efficacious. Pharmacokinetic studies suggest that consistent adherence is required to achieve sufficient concentrations of tenofovir in vaginal tissues and a substantial proportion of women across studies attained this level of high adherence. The lack of a protective effect observed in FEM-PrEP and VOICE can be attributed to overall low adherence to study medication and is not because of biological features unique to women [50, 51] . Although adherence challenges observed across all trials have important implications for PrEP delivery to women, they should not detract from the overall conclusion that PrEP protects women from HIV acquisition when taken with sufficient adherence (Fig. 1 ).
DELIVERING PREEXPOSURE PROPHYLAXIS TO WOMEN
The next steps for PrEP delivery to women include implementation within routine healthcare, in the context of a now-proven protective benefit from PrEP and without the incentives of clinical trials. Clinical trial data suggest that PrEP is tolerant of some missed doses, and additional research is needed to understand how many doses can be missed and still provide HIV protection for women, as well as whether that differs in the presence of cofactors influencing HIV susceptibility.
Integrating time-limited preexposure prophylaxis into existing reproductive health services ]. Providers can use risk scoring tools to identify women with the highest risk for HIV acquisition using routinely collected clinical and demographic data [60, 61] .
Facilitating adherence in public health settings
Individuals' adherence patterns changed relatively little during the clinical trials; in general, those who initiated PrEP maintained their adherence, especially if they adhered through the end of the first month [11 && ,15 && ]. Greater public health impact may come from prioritizing PrEP for those who will achieve this sustained high adherence, directing adherence support to the subset with adherence challenges, and assisting women to assess their risk and match PrEP use with their most vulnerable periods [58 & ]. PrEP delivery to women must be coupled with realistic expectations of and mechanisms to facilitate adequate adherence, including personal risk assessment and social support [24 & ,62-64]. Community sensitization regarding antiretroviral medications for prevention, not just treatment, of HIV may create a context that is more receptive to PrEP use. When it is safe for a woman to share her desire for HIV prevention, her invitation to a male partner to participate in decision-making about PrEP may facilitate her high adherence.
Initial data suggest that adherence to and HIV protection from PrEP is higher in open label-studies when the HIV prevention benefit is well understood by users. Among MSM enrolled in the PROUD (Preexposure option for reducing HIV in the UK) study, high self-reported adherence to daily oral TDF-based PrEP was substantiated by blood tenofovir levels and provided 86% protection from HIV [65 && ]. Among HIV serodiscordant couples enrolled in the Partners Demonstration Project using PrEP as a 'bridge' until the HIV-infected partner sustains ART use, tenofovir was detected in 86% of samples tested and contributed to an estimated 96% reduction in HIV [66 && ,67 && ]. Open-label studies also suggest that adherence to daily dosing may be preferred over intermittent or event-driven dosing, perhaps because it fits into daily routines and does not require anticipating sex [68 && ,69] . In ADAPT (Alternative Dosing to Augment Pre-Exposure Prophylaxis Pill Taking) (HPTN 067), an open-label study of oral PrEP dosing frequency among young South African women, adherence was assessed through Wisepill monitoring. Women randomized to a daily dosing schedule had higher adherence overall and 75% of sexual acts covered by PrEP, as compared with 52-56% of sex acts among women randomized to less than daily or intermittent dosing to align with sexual activity [68 && ]. Long-acting formulations of PrEP delivered as injectables or vaginal rings, including multipurpose technologies that provide dual protection against HIV and unintended pregnancy, are currently being evaluated and may provide alternative strategies to daily oral PrEP in the future [ ]. Analogous to contraception, for which multiple methods permit choices to accommodate individual women's needs, multiple delivery mechanisms for PrEP may allow more women to achieve HIV protection [74] .
Factors influencing women's adherence to daily oral PrEP

CONCLUSION
Tenofovir-based oral PrEP is an effective HIV prevention strategy for heterosexual women. Significant public health impact from PrEP will require delivery strategies that integrate PrEP into existing health services and address the individual, community, and structural level factors that influence adherence. More than 30 years into the HIV epidemic, oral PrEP is the first intervention that women can control themselves and it offers highly efficacious prevention against HIV.
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